Skip to content
Open access

Tarlatamab: Invaluable Time for Patients With Extensive-Stage Small Cell Lung Cancer.

Sep 2026 · Clinical Journal of Oncology Nursing · Vol 30 5, pp. 347-351 · 0 citations
Medicine

TL;DR

Tarlatamab-dlle (tarlatamab), a bispecific T-cell engager targeting delta-like ligand 3, offers a novel therapeutic option f.

Abstract

Extensive-stage small cell lung cancer (ES-SCLC) remains highly aggressive and has a poor prognosis. Tarlatamab-dlle (tarlatamab), a bispecific T-cell engager targeting delta-like ligand 3, offers a novel therapeutic option f.

Read PDF

Similar papers

Open access 2026

Identification of TXNDC16 Expression Pattern in Small Cell Lung Cancer

A large number of patients with small cell lung cancer are diagnosed with atypical neuroendocrine or non-neuroendocrine subtypes, which is an aggressive malignancy characterized by rapid progression, early metastasis, and molecular heterogeneity.

Anna M. Dmitrieva, Qian Yang, Ramona Lesch et al. · 0 citations
Open access Oct 2026

Key Challenges on the Path toward Precision Immunotherapy for Large B-cell Lymphoma.

Cell and immune therapies have transformed the outcomes of patients with lymphoma, but the majority of patients do not have durable benefit. Here, we provide our perspective on key challenges in personalizing cell and immune therapy approaches for lymphoma through discovery, validation, and clinical deployment of micro...

Xu-Bin Li, Christopher R. Flowers, Michael R. Green · 0 citations
Open access Oct 2026

SRC Activation Drives Acquired Pemetrexed Resistance in Non‐Small Cell Lung Cancer and Is Targetable by Dasatinib

Pemetrexed, a standard antifolate chemotherapy for non‐squamous non‐small cell lung cancer (NSCLC), is often limited by acquired resistance. We investigated whether SRC kinase mediates pemetrexed resistance and whether SRC inhibition can suppress survival signaling in pemetrexed‐resistant NSCLC cells.

Jeongmin Seo, Kui-Jin Kim, Se Hyun Kim et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.